Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Journal article

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.

Authors: Holman, R; Bethel, M; Chan, J; Chiasson, J; Doran, Z

• Publication status: Published
• Publisher: Mosby Inc.
• Journal: American heart journal
• Volume: 168
• Issue: 1
• Pages: 23-9.e2
• Publication date: 2014-07-01
• DOI: 10.1016/j.ahj.2014.03.021
• EISSN: 1097-6744
• ISSN: 0002-8703
• Language: English
• Keywords: Coronary Disease; ACE Study Group; Diabetes Mellitus, Type 2; Acarbose; Hypoglycemic Agents; Humans; Disease Progression; Treatment Outcome; Follow-Up Studies; Prospective Studies; Glucose Intolerance; Blood Glucose; Secondary Prevention; Double-Blind Method